Case Report
Medroxyprogesterone in Metastatic Renal Cell Carcinoma
Abstract
ALTHOUGH VARIABLE DEGREES of subjective responses have been described in patients with advanced renal cell carcinoma (RCC) treated with medroxyprogesterone acetate (MPA), only few complete regressions have been reported.1,2 We describe complete regression of pulmonary metastases in a patient receiving MPA.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
